Circulating enterolactone and risk of endometrial cancer
2006 (English)In: International Journal of Cancer, ISSN 0020-7136, Vol. 119, no 10, 2376-2381 p.Article in journal (Refereed) Published
It has been suggested that phytoestrogens protect against hormone-dependent cancers. Lignans are the main class of phytoestrogens in Western diets. We conducted a prospective study of endometrial cancer and circulating levels of the main human lignan, enterolactone. The design was a case-control study nested within 3 prospective cohort studies, in New York, Sweden and Italy. Serum or plasma samples had been collected at enrollment and stored at -80 degrees C. A total of 153 cases, diagnosed a median of 5.3 years after blood donation, and 271 matched controls were included. No difference in circulating enterolactone was observed between cases (median, 19.2 nmol/L) and controls (18.5 nmol/L). Adjusting for body mass index, the odds ratio for the top tertile of enterolactone, as compared to the lowest was 1.2 (95% CI, 0.7-2.0; p for trend = 0.53). Lack of association was observed in both pre- and postmenopausal women. No correlation was observed between enterolactone and circulating estrogens or SHBG in healthy postmenopausal women. These results do not support a protective role of circulating lignans, in the range of levels observed, against endometrial cancer.
Place, publisher, year, edition, pages
2006. Vol. 119, no 10, 2376-2381 p.
Endometrial cancer, prospective study, nested case-control study, enterolactone, lignan, phytoestrogen
IdentifiersURN: urn:nbn:se:umu:diva-13856DOI: doi:10.1002/ijc.22140PubMedID: 16929490OAI: oai:DiVA.org:umu-13856DiVA: diva2:153527